SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum to expand in AI data-center optics is driving attention, as traders focus on dilution, the deals scale, and its lengthy closing timeline amid a sharp selloff. Some see the move as an expensive, risky deal for shareholders, while others argue the strategic fit could strengthen Marvells position in AI connectivity over the long term.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is selling off with the semiconductor sector after Intels disappointing results and guidance heightened concerns about chip demand and AI spending. Traders disagree over whether the move is sympathy selling or a warning for AMD, with the companys Q3 results and guidance in focus; some see a buying opportunity while others cite valuation and downside risk.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with the shares selling off as traders focus on the fixed exchange ratio, exposure to Marvells stock, and the long wait for closing. Many see the terms as unfavorable to Lumentum holders, while others argue the combination has strategic value in AI optics and are buying the decline.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

The steep selloff is widely attributed by traders to Usonas competing NDA filing and concern that Compass Pathways has yet to complete its own NDA submission. The community is divided over how serious the competitive threat issome see Usona as a first-mover risk, while others point to differences in indications and Usonas nonprofit structureand is looking for management to clarify Compasss regulatory timeline.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

CEO Wes Cummins CNBC comments that substantial planned data-center capacity still needs financing have intensified concerns about borrowing costs, dilution and execution amid a broader selloff in AI infrastructure stocks. Traders are split between those worried about funding risk and those pointing to long-term hyperscaler leases and continued demand as support for the business outlook.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off amid fears that Kioxias cautious outlook signals slowing NAND pricing growth, adding to broader weakness in memory and AI-related stocks despite SanDisks strong results and guidance. Traders are divided between concerns that earnings growth may be peaking and bullish arguments that demand and company fundamentals remain strong.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention amid a sharp, volatile retreat alongside AI and optics stocks, with traders debating whether concerns about AI spending and valuations justify the selloff or whether it is an opportunity ahead of earnings. Bulls point to data-center transceiver demand and capacity expansion, while bears focus on customer concentration, dilution and execution risks.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharp selloff is being tied to a weaker-than-expected fourth-quarter outlook, with supply constraints and softer PC demand weighing despite a strong recent quarter. Traders are split between viewing the decline as an oversold buying opportunity and expecting further losses, amid broader pressure on technology and semiconductor stocks.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings report is the dominant focus, with traders weighing holiday-quarter guidance and iPhone Duo demand against rising memory costs and a high valuation. Views are sharply split between hopes that a strong report will sustain the stocks relative strength and fears of a post-report pullback, with many seeing Apple as a potential driver of broader tech and index direction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff alongside other AI data-center and neocloud stocks has focused discussion on whether the capital-intensive buildout can be funded and executed without more debt or dilution, with upcoming earnings and guidance seen as a test. Bears fear further downside amid weak sentiment, while bulls argue that AI-compute demand and customer commitments support the long-term thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday

U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.read more...

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares

Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.read more...

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Key PointsAn Oruka Therapeutics executive reported selling 9,854 directly held Common Stock shares for a total value of $687K based on a weighted average price of $69.72 per share as of June 15, 2026...

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Key PointsArjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026...

Monday Sector Leaders: Biotechnology, Shipping Stocks

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of Apogee Therapeutics, up about 46.8% and shares of Oruka Therapeutics up about 18.1% on the day.

Also showing relative strength are shipping shares, u...

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

iShares Russell 2000 ETF

SPDR S&P Biotech ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORKA News